



MINUTES

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, November 16, 2017
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128

Committee Members Present:

Clinton Sheffield, MD
Abril Atherton, PharmD
Bryan Larson, PharmD
Clayton Grace, RPh

Elizabeth Young, PharmD
Keith Tolman, MD
McKay Robinson, PharmD
Susan Siegfried, MD

Committee Members Excused:

Jake Jones, MD

Dept. of Health/Div. of Health Care Financing Staff Present:

Sue Leong, RPh., Pharmacy Director
Andrea Rico, CPhT
Heather Santacruz, RN

Merelynn Berrett, RN
Robyn Seely, PharmD

University of Utah Drug Regimen Review Center Staff Presenters:

Valerie Gonzales, PharmD
Elena Martinez Alonso, BPharm, MSc MTSI, Medical Writer

Other Individuals Present:

Jeff Mussack, Otsuka
Rick Kegler, Otsuka
Joanne LaFleur, U of U
Clayne Garrett, BIPI

Lori Howarth, Bayer
Charissa Anne, J&J
Cody Ball, SelectHealth

Meeting conducted by: Committee Chair

1. **Welcome & Housekeeping:** Clinton Sheffield opened the meeting and reminded everyone to sign the rosters. He welcomed the newest member of the P&T Committee, McKay Robinson.
2. **Review and Approval of October Minutes:** Clayton Grace made a motion to approve the minutes from October. Bryan Larson seconded the motion. Six in favor, McKay Robinson and Clinton Sheffield Abstained; motion passed.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to review data provided by the DRRC regarding Pediatric Antibiotic Over-Use.
4. **DPP-4 Inhibitors/ DPP-4 Inhibitor Combinations:** Valerie Gonzalez presented a review of DPP-4 Inhibitors and DPP-4 Inhibitor Combinations. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical

trials, disease-state treatment guidelines and Utah Medicaid utilization data.

5. **Public Comment:** None
6. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other States' Medicaid programs.
7. **Committee Discussion:** Clinton Sheffield made a motion that all DPP-4 Inhibitors/ DPP-4 Inhibitor Combinations are equally safe and efficacious. Clayton Grace seconded the motion. Seven in favor, Keith Tolman abstained; motion passed. Clinton Sheffield made a motion that one mono therapy and one combo therapy with metformin should be included on the PDL as preferred. Susan Siegfroid seconded the motion. Seven in favor, Keith Tolman abstained; motion passed.
8. **Public Meeting Adjourned:** Clinton Sheffield motioned to close the meeting. Keith Tolman seconded the motion. Unanimous Approval.
9. **Next meeting is scheduled for** January 18, 2018 Antiplatelet Agents.

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>